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Enterococcus faecium has emerged as an important nosocomial pathogen worldwide, and this trend has
been associated with the dissemination of a genetic lineage designated clonal cluster 17 (CC17). Entero-
coccal isolates were collected prospectively (2006 to 2008) from 32 hospitals in Colombia, Ecuador, Peru´,
and Venezuela and subjected to antimicrobial susceptibility testing. Genotyping was performed with all
vancomycin-resistant E. faecium (VREfm) isolates by pulsed-field gel electrophoresis (PFGE) and mul-
tilocus sequence typing. All VREfm isolates were evaluated for the presence of 16 putative virulence genes
(14 fms genes, the esp gene of E. faecium [espEfm], and the hyl gene of E. faecium [hylEfm]) and plasmids
carrying the fms20-fms21 (pilA), hylEfm, and vanA genes. Of 723 enterococcal isolates recovered, E. faecalis
was the most common (78%). Vancomycin resistance was detected in 6% of the isolates (74% of which were
E. faecium). Eleven distinct PFGE types were found among the VREfm isolates, with most belonging to
sequence types 412 and 18. The ebpAEfm-ebpBEfm-ebpCEfm (pilB) and fms11-fms19-fms16 clusters were
detected in all VREfm isolates from the region, whereas espEfm and hylEfm were detected in 69% and 23%
of the isolates, respectively. The fms20-fms21 (pilA) cluster, which encodes a putative pilus-like protein,
was found on plasmids from almost all VREfm isolates and was sometimes found to coexist with hylEfm and
the vanA gene cluster. The population genetics of VREfm in South America appear to resemble those of
such strains in the United States in the early years of the CC17 epidemic. The overwhelming presence of
plasmids encoding putative virulence factors and vanA genes suggests that E. faecium from the CC17
genogroup may disseminate in the region in the coming years.
Enterococci are now recognized as important nosocomial
pathogens worldwide and in the United States are ranked as
the second most common cause of nosocomial infections,
after staphylococci (14). The two most common enterococ-
cal species isolated from clinical samples are Enterococcus
faecalis and E. faecium; however, the proportions of isolates
of these two species have dramatically changed in the last
decade. Whereas up until the early to mid-1990s E. faecalis
was the overwhelmingly predominant species isolated in
U.S. hospitals (37), by 2008, the proportion of nosocomial E.
faecalis/E. faecium strains was ca. 1.5:1, and there was an
important increase in the incidence of E. faecium nosoco-
mial infections (14). Moreover, more than 80% of E. fae-
cium isolates currently recovered from U.S. hospitals are
resistant to vancomycin, and virtually all of them (90%)
exhibit ampicillin resistance (14). On the contrary, the prev-
alence of vancomycin resistance in E. faecalis remains low
(7% of isolates), and ampicillin resistance continues to be
extremely rare. This change in the epidemiology of entero-
coccal infections has been attributed to the increased ability
of a genogroup of E. faecium (designated clonal cluster 17
[CC17]) to colonize the gastrointestinal tract of humans,
cause disease (37), and exhibit high levels of resistance to
most antienterococcal antibiotics. Several virulence and col-
onizing factors have been postulated to explain this in-
creased virulence (4, 25, 28) and include the following: (i)
the presence of an intact acm gene, which encodes a colla-
gen adhesin and which has been associated with the patho-
genesis of endocarditis in members of CC17 (25); (ii) the esp
gene of E. faecium (espEfm), which codes for an enterococcal
surface protein, which has been shown to play a role in
biofilm formation (12), and which transiently aggravates
experimental urinary tract infection (18); (iii) the fms (E.
faecium surface protein-encoding) genes, which encode cell
wall-anchored proteins, including subunits of the enterococ-
cal pili (13, 31); and (iv) the hyl gene of E. faecium (hylEfm;
which encodes a putative glycosyl hydrolase), which is car-
ried by transferable plasmids that have been shown to in-
crease the ability of a laboratory strain of E. faecium to
colonize the gastrointestinal tracts of mice and also enhance
the virulence of a commensal strain of E. faecium in exper-
imental peritonitis (4, 28).
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In South America (Brazil and Argentina), vancomycin-resis-
tant (VR) enterococcal infections have been described since
1998 (9, 20). In a prospective multicenter surveillance study
conducted in 2003, the prevalence of VR among enterococci in
Colombia was found to be lower (9.7%) than that in the
United States (1), and the isolation of similar percentages of
VR enterococci has been described more recently (21). Al-
though the emergence of E. faecium CC17 has been docu-
mented in Brazil, Chile, and Paraguay (16, 19, 39), prospective
studies have not been performed and limited data regarding
the presence of the potential virulence determinants of CC17
E. faecium (including hylEfm-containing plasmids) in South
America are available. Thus, we performed a multinational,
multicenter prospective surveillance study with the aim of
characterizing the population genetics of enterococci circulat-
ing in the northern region of South America. Clinical isolates
(excluding colonizing isolates) were collected prospectively
from 32 hospitals in four countries (Colombia, Ecuador, Peru´,
and Venezuela) and were further characterized at the molec-
ular level.
(This study was presented in part at the 48th Annual Inter-
science Conference on Antimicrobial Agents and Chemother-
apy/Infectious Diseases Society of America 46th Annual Meet-
ing, Washington, DC, 25 to 28 October 2008, abstr. C2-1998.)
MATERIALS AND METHODS
Specimen collection. A multicenter study was performed from February 2006
through February 2008 to evaluate the molecular epidemiology of enterococci in
four South American countries. Each participating tertiary-care hospital (a total
of 32 hospitals, from the Latin American Network of Antimicrobial Resistance)
in Colombia (22 hospitals in six cities), Ecuador (5 hospitals in one city), Peru´ (3
hospitals in one city), and Venezuela (2 hospitals in one city) collected consec-
utive enterococcal isolates (duplicate organisms from the same patient were
excluded). The samples were collected by the clinical laboratory from each
participating hospital and corresponded to samples from hospitalized patients in
Colombia, Peru´, and Venezuela. In Ecuador, the clinical laboratory also col-
lected samples from ambulatory services and outpatient clinics. The isolates
originated from the following clinical specimens: blood, urine, secretions from
surgical wounds, peritoneal fluid, abdominal abscesses, joint aspirates, osteomy-
elitis aspirates, pleural fluid, pericardial effusion, cerebral abscesses, and cere-
brospinal fluid (CSF). In an attempt to avoid isolates that likely represented
colonization, enterococci recovered from sputum, rectal swabs, catheters, or skin
(unless they originated in an infected surgical wound) were excluded. Each
hospital identified the microorganisms by using either automated methods (per-
formed with the Vitek or MicroScan system) or manual methods, and once the
corresponding isolate was included in the study, it was sent to the reference
laboratory (located in Bogota´, Colombia) via courier in transport medium
(Amies; BBL). Upon arrival, the reference laboratory confirmed the purity of the
isolate and confirmed the identification by molecular methods using multiplex
PCR for enterococci (see below).
Susceptibility testing and molecular methods for species-specific identifica-
tion and van genotype determination. Susceptibility tests for enterococci were
performed by an agar dilution method with ampicillin, ciprofloxacin, chloram-
phenicol, linezolid, vancomycin, and teicoplanin. The isolates were also evalu-
ated for high-level resistance (HLR) to streptomycin (2,000 g/ml) and genta-
micin (500 g/ml). All isolates from blood and CSF identified as E. faecalis were
screened for the presence of the -lactamase enzyme by use of a nitrocefin test,
and all susceptibility tests were conducted by the methodology suggested by the
CLSI (8). MIC determinations were carried out with the inclusion of a control
reference strain (E. faecalis ATCC 29212). Species-specific identification of the
enterococci and determination of the van genotype of the vancomycin-resistant
isolates were performed by PCR, as described previously (2, 10) (primers for the
detection of the recently described vanL genotype [6] were not included). E.
faecium BM4147 (vanA), E. faecalis V583 (vanB), and E. gallinarum BM4174
(vanC1) were used as control strains for MIC determinations and PCR assays.
Molecular typing. Pulsed-field gel electrophoresis (PFGE) of the vancomycin-
resistant E. faecium (VREfm) isolates was performed by use of some modifica-
tions of a previously described method (22), and the banding patterns were
initially interpreted by visual inspection, according to the criteria specified by
Tenover et al. (35). Subsequently, cluster analysis was performed by the method
of Dice and the unweighted-pair group method using average linkages
(UPGMA). The band tolerance was set at 1.5%, and the threshold cutoff value
was set at 85%. Representative isolates of each PFGE subtype of VREfm were
further genotyped by multilocus sequence typing (MLST) by a standard protocol
described previously (15, 29). Fragments of seven housekeeping genes (atpA, ddl,
gdh, purK, gyd, pstS, and adk) were sequenced, the allelic profiles were obtained,
and the sequence type (ST) for each unique allelic profile was designated on the
basis of the information at the MLST website (http://efaecium.mlst.net).
Detection of plasmids and putative virulence genes. The preparation of colony
lysates on nylon membranes and hybridization under high-stringency conditions
were performed as described previously (33). DNA probes for the hylEfm, espEfm,
and 14 fms genes were obtained by using previously published primers (11, 27,
32); the probes were radiolabeled by use of the RadPrime DNA labeling system
(Invitrogen, Carlsbad, CA). Plasmid detection in representative isolates of
VREfm belonging to CC17 was performed by the use of S1 nuclease and PFGE,
according to a previously described protocol (4, 5). This methodology allows the
detection and estimation of the size of large bacterial plasmids in the presence of
genomic DNA by PFGE (5). Plasmid bands were subsequently hybridized with
probes targeting the hylEfm, fms20, fms21 (pilA), and vanA genes to determine if
these genes were colocated in the same plasmid, as was reported previously (17).
E. faecium TX0016 (strain DO) (23) and ERV-99 (4) were used as controls for
colony hybridizations and the PFGE-S1 nuclease experiments.
RESULTS
Phenotypic characteristics of enterococcal isolates from the
northern region of South America. A total of 760 consecutive
Enterococcus sp. isolates was collected in the four countries.
Thirty-seven isolates were not included in the study due to
protocol violations (contamination, isolates were from the
same patient, the source was not included in the protocol, or
misidentification). Among the isolates included (a total of
723), Colombian hospitals contributed 309 (43%) of the iso-
lates, Peruvian hospitals contributed 164 (23%), Ecuadorian
hospitals contributed 148 (20%), and Venezuelan hospitals
contributed 102 (14%). The majority (78%) were E. faecalis
isolates mostly recovered from urine (54%) and blood (14%)
(no -lactamase-producing isolate was detected). E. faecium
comprised 15% (n  111) of the enterococcal isolates (Table
1). The most common clinical sources of E. faecium included
urine (38%), blood (21%), and surgical wound infections
(13%). Other enterococcal species also identified by PCR in-
cluded E. avium, E. hirae, E. casseliflavus, E. gallinarum, and E.
durans. We were unable to determine the enterococcal species
for 5% (n  35) of the isolates.
The resistance rates of the enterococci from the Andean
region are shown in Table 1. All E. faecalis isolates were sus-
ceptible to ampicillin and linezolid, whereas the rates of HLR
to gentamicin and streptomycin were 28% and 30%, respec-
tively; ciprofloxacin resistance was found in 29% of the E.
faecalis isolates (Table 1). In contrast, the rates of resistance to
ampicillin and vancomycin and HLR to gentamicin and strep-
tomycin in E. faecium were much higher (76%, 31%, 36%, and
44%, respectively). The highest rates of resistance to ampicillin
and vancomycin and HLR to gentamicin and streptomycin in
E. faecium isolates were found in Peru´ (90%, 48%, 55%, and
65%, respectively), and the lowest were found in Venezuela
(50%, 25%, 8%, and 21%, respectively). Among the ampicil-
lin-resistant E. faecium isolates from the Andean region, a
total of 51 isolates (46%) had MICs of 64 g/ml. Linezolid
was active against all the E. faecium isolates tested, and only
VOL. 48, 2010 ENTEROCOCCI IN LATIN AMERICAN HOSPITALS 1563
4% of the E. faecium isolates tested were resistant to chlor-
amphenicol.
E. faecium CC17 is also predominant in the northern region
of South America. Thirty-five VREfm isolates were found, and
all of them exhibited the VanA phenotype (high levels of
resistance to both vancomycin and teicoplanin) and harbored
the vanA gene cluster. Typing by PFGE revealed 11 different
banding patterns (patterns A to K) (Fig. 1). A single PFGE
banding pattern was predominant in each country (referred to
as type A in Venezuela, type B in Peru´, type C in Colombia,
and type D in Ecuador) (Fig. 1), although isolates from differ-
ent countries (e.g., types A and E) could be found to have
related PFGE types. MLST analysis of representative isolates
of each PFGE type indicated that the most frequent ST was
ST412; other STs included ST17, ST18, ST125, ST203, ST280,
and ST282 (all of which were associated with the CC17 genetic
lineage). A representative of PFGE pattern J from a Peruvian
hospital was found to belong to a novel ST (ST494) which had
not been reported previously.
Only three vancomycin-resistant E. faecalis were isolated in
the 2 years of the study; all three isolates were recovered in
Colombia, harbored the vanB gene cluster, and were previ-
ously characterized as belonging to the same unique clonal
cluster that has been circulating in that country since 2001
(ST2 by trilocus sequence typing and MLST) (3, 7).
CC17 vancomycin-resistant E. faecium isolates from South
America are enriched in the fms genes. It had previously been
shown that the members of CC17 of E. faecium harbor a
number of genes encoding sortase-anchoring motif (LPXTG)-
containing cell wall proteins (13, 31); at least 15 of these genes
encode predicted microbial surface components recognizing
adhesive matrix molecule (MSCRAMMs) proteins in a U.S.
strain (strain TX0016 [strain DO]) that was sequenced (32). It
has been proposed that these genes function as important
virulence determinants mediating adhesion to mammalian tis-
sues, and several are enriched in the CC17 genogroup (11, 13,
31). Thus, we set out to investigate if these genes were also
frequently found in CC17 isolates of E. faecium from Latin
America. Figure 2 shows the results of colony hybridizations of
isolates with several putative virulence genes (including 14 of
the fms genes; acm, which may be present as an intact gene or
pseudogene, was not tested since it has been detected in almost
all isolates studied previously [26]). Indeed, the four clusters of
genes encoding MSCRAMM proteins (31) were highly repre-
sented among the South American E. faecium isolates tested.
The ebpAEfm-ebpBEfm-ebpCEfm (pilB) and fms11-fms19-fms16
clusters, which harbor genes encoding putative proteins with
conserved pilin motifs and E-boxes of pilus proteins of Gram-
positive bacteria, were present in all our South American VR
isolates (Fig. 2). Interestingly, the scm gene, which has been
shown to encode a collagen adhesin (the second collagen ad-
hesin from E. faecium), was present in more than 90% of the
isolates. The other fms genes were also frequently present at
rates ranging from 67% to 97% in the VREfm isolates. The
espEfm and hylEfm genes, which have previously been associated
with CC17 (28, 38), were detected in South American VR E.
faecium isolates (69% and 23% of isolates, respectively).
TABLE 1. Resistance profiles of enterococci from the northern region of South America
Organism
(no. of isolates)
% (no.) of isolates resistant to the following antimicrobial agentsa:
VAN TEC CIP CHL LZD AMP HLR-GEN HLR-STR
Enterococci
Colombia (309) 5 (16) 3 (10) 30 (93) 12 (38) 0 (0) 10 (31) 19 (60) 29 (89)
Perú (164) 9 (15) 8 (14) 55 (91) 17 (28) 0 (0) 16 (27) 53 (87) 47 (77)
Ecuador (148) 5 (7) 3 (5) 25 (37) 17 (26) 0 (0) 10 (15) 28 (42) 28 (42)
Venezuela (102) 9 (9) 6 (6) 28 (29) 9 (9) 0 (0) 12 (12) 15 (15) 17 (17)
Total (723) 6 (47) 5 (35) 35 (250) 14 (101) 0 (0) 12 (85) 28 (204) 31 (225)
Enterococcus faecalis
Colombia (251) 1 (3) 0 (0) 26 (65) 13 (33) 0 (0) 0 (0) 17 (44) 27 (67)
Perú (128) 0 (0) 0 (0) 48 (61) 20 (26) 0 (0) 0 (0) 54 (69) 44 (56)
Ecuador (122) 0 (0) 0 (0) 22 (27) 20 (25) 0 (0) 0 (0) 26 (32) 27 (33)
Venezuela (59) 0 (0) 0 (0) 19 (11) 13 (8) 0 (0) 0 (0) 22 (13) 17 (11)
Total (560) 0.5 (3) 0 (0) 29 (164) 16 (92) 0 (0) 0 (0) 28 (158) 30 (167)
Enterococcus faecium
Colombia (41) 24 (10) 24 (10) 61 (25) 7 (3) 0 (0) 76 (31) 34 (14) 44 (18)
Perú (29) 48 (14) 48 (14) 93 (27) 3 (1) 0 (0) 90 (26) 55 (16) 65 (19)
Ecuador (17) 29 (5) 29 (5) 59 (10) 0 (0) 0 (0) 88 (15) 47 (8) 41 (7)
Venezuela (24) 25 (6) 25 (6) 58 (14) 4 (1) 0 (0) 50 (12) 8 (2) 21 (5)
Total (111) 31 (35) 31 (35) 68 (76) 4 (5) 0 (0) 76 (84) 36 (40) 44 (49)
Other enterococcal species
Colombia (17) 18 (3) 0 (0) 18 (3) 12 (2) 0 (0) 0 (0) 12 (2) 23 (4)
Perú (7) 14 (1) 0 (0) 43 (3) 14 (1) 0 (0) 14 (1) 28 (2) 28 (2)
Ecuador (9) 22 (2) 0 (0) 0 (0) 11 (1) 0 (0) 0 (0) 22 (2) 22 (2)
Venezuela (19) 16 (3) 0 (0) 21 (4) 0 (0) 0 (0) 0 (0) 0 (0) 5 (1)
Total (52) 17 (9) 0 (0) 19 (10) 8 (4) 0 (0) 2 (1) 11 (6) 17 (9)
a VAN, vancomycin; TEC, teicoplanin; CIP, ciprofloxacin; CHL, chloramphenicol; LZD, linezolid; AMP, ampicillin; HLR-GEN, high-level resistance to gentamicin;
HLR-STR, high-level resistance to streptomycin.
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The fms20-fms21 (pilA) cluster and hylEfm are carried on
plasmids associated with the vanA gene in South American
VREfm. It was previously shown that hospital-associated E.
faecium isolates from diverse geographical locations carry
large, transferable plasmids containing the hylEfm gene (which
encodes a putative family 84 glycosyl hydrolase enzyme) that,
additionally, are associated with vancomycin and aminoglyco-
side resistance genes (4). These hylEfm-containing plasmids
have emerged as important virulence and colonization deter-
minants of CC17 of E. faecium (4, 28). More recently, one of
the fms clusters (fms20-fms21 [pilA]) encoding pilus-like pro-
teins was also found to be located in a large hylEfm-carrying
plasmid in U.S. strain TX0016 (strain DO) (17). Table 2 and
Fig. 3 show the results of S1 nuclease digestion; PFGE; and the
hybridization of representatives of South American VR E.
faecium isolates with probes targeting the fms20-fms21 (pilA)
cluster, hylEfm, and vanA. When it was present, the fms20-
fms21 (pilA) cluster was always encoded on plasmids ranging
from ca. 60 kb to 242 kb. Of note, in some strains, fms21-
containing plasmids were found not to harbor the other mem-
ber of the cluster (fms20), and in three strains (all from Peru´)
an additional copy of fms21 was detected in a different plasmid
(strains P575, P1139, and P1986; Table 2 and Fig. 3). Further-
more, the fms20-fms21 cluster was found to be in the same
plasmid as hylEfm in three strains (estimated plasmid sizes, 190
and 230 kb) and on the same vanA-containing plasmid in three
strains (Table 2). No plasmid was found to carry the fms20-
fms21 cluster, hylEfm, and vanA together.
DISCUSSION
In the work described here, we performed the first prospec-
tive, multinational study evaluating the molecular epidemiol-
ogy of VR enterococci in the northern region of South Amer-
ica. Our results indicate that the prevalence of vancomycin
resistance is relatively low in the participating countries (only
6% of isolates included in this study) compared to that in the
United States. In our previous multicenter study performed
with isolates from 15 hospitals in Colombia in 2001 and 2002,
the rate of vancomycin resistance among enterococcal isolates
was 9.7%. Also, unlike in the United States, E. faecalis contin-
ues to be, by far, the most frequent enterococcal species iso-
FIG. 1. Molecular typing of VR E. faecium from the Andean region of South America. The phylogenetic tree was constructed by use of the
Dice coefficient and UPGMA clustering; the band tolerance was set at 1.5%, and the threshold cutoff value was set at 85%. ST, sequence type;
CC17, clonal cluster 17.
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lated in this region (ratio of E. faecalis to E. faecium, 5:1).
Vancomycin resistance in E. faecalis was found sporadically in
only three isolates from one city of the participating countries,
and ampicillin was active against all E. faecalis isolates, under-
scoring the fact that -lactams and glycopeptides continue to
be useful for the treatment of enterococcal infections in the
northern region of South America. On the other hand, the
rates of HLR to aminoglycosides in E. faecalis were ca. 30%,
and there were important regional variations; for example, in
the participating hospitals from Peru´, more than 50% of the E.
faecalis isolates exhibited HLR to gentamicin and 44% exhib-
ited HLR to streptomycin, indicating that the treatment of
endovascular infections with the combination of a cell wall
agent and an aminoglycoside in some areas of South America
FIG. 2. Frequency of detection of putative virulence genes in 35 VR E. faecium isolates from the Andean region of South America. The
numbers on the left-hand side indicate the four clusters of genes encoding characterized putative proteins of the enterococcal pili (30).
TABLE 2. Plasmid or chromosomal location of fms20, fms21 (pilA), hylEfm, and vanA in vancomycin-resistant Enterococcus faecium isolates
from the Andean region of South America
Country Code Source PFGEtype ST
Plasmid or chromosomal locationa
Estimated plasmid size(s)
fms20 fms21(pilA) hylEfm vanA
Perú P575 Urine G 280  (P)  (P)  (P)  (P) hylEfm and fms20-fms21, 190 kb;
fms21, 70 kb; vanA, 60 kb;
P1123 Blood B 412  (P)  (P)   (P) fms20-fms21, 70 kb; vanA, 48 kb
P1137 Wound infection E 18     (P) vanA, 60 kb
P1139 Urine F 280  (P)  (P)   (P) fms20-fms21, 190 kb; fms21, 70
kb; vanA, 48 kb
P1140 Wound infection A 412  (P)  (P)   (P) fms20-fms21 and vanA, 60 kb
P1190 Blood E 125  (P)  (P)  (P)  (P) hylEfm and fms20-fms21, 230 kb;
vanA, 60 kb
P1985 Urine B 412  (P)  (P)   (P) fms20-fms21, 200 kb; vanA, 48 kb
P1986 Blood J 494  (P)  (P)   (C) fms20-fms21, 80 kb; fms21, 60 kb
P2022 Abdominal abscess H 282  (P)  (P)   (P) fms20-fms21, 75 kb; vanA, 60 kb
P2074 Blood F NDb  (P)  (P)  (P)  (P) hylEfm and fms20-fms21, 220 kb;
vanA, 70 kb
Colombia C497 Blood C 18    (P)  (P) hylEfm and vanA, 160 kb
C621 Peritoneal fluid A 412   (P)   (P) fms21 and vanA, 60 kb
C1688 Blood C ND  (P)  (P)   (C) fms20-fms21, 180 kb
C1904 Blood E ND    (P)  (P) hylEfm and vanA, 160 kb
C1910 Urine C 18  (P)  (P)   (P) fms20-fms21, 180 kb; vanA, 48 kb
Ecuador E417 Blood D 17  (P)  (P)   (P) fms20-fms21, 180 kb; vanA, 48kb;
E422 Urine I 203  (P)  (P)   (C) fms20-fms21, 70 kb
Venezuela V689 Wound infection A 412  (P)  (P)   (P) fms20-fms21 and vanA, 60 kb
V2216 Abdominal abscess A ND  (P)  (P)   (P) fms20-fms21 and vanA, 70 kb
a P, plasmid; C, chromosomal.
b ND, not done; MLST was not performed because the isolate had a PFGE pattern closely related to that of another isolate whose MLST profile was determined.
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may be challenging and alternative bactericidal therapies
should be sought. Also, we did not find important differences
in phenotypic or genotypic characteristics between VREfm
isolates from urine and blood (except that the blood isolates
had higher rates of resistance to chloramphenicol [20%] than
those VREfm isolates that originated in urine [0%]).
Although our findings indicate that the proportion of E.
faecalis/E. faecium is considerably higher in South American
hospitals than in U.S. hospitals (14), the South American
VREfm isolates have genotypic and phenotypic characteristics
similar to those of their U.S. counterparts: (i) South American
VREfm isolates mostly belong to ST412 and ST18 (the CC17
lineage), indicating that a hospital-associated genetic lineage is
present in the region and supporting previous findings of stud-
ies performed in other countries of South America (16, 19, 39);
(ii) the South American CC17 VREfm isolates also harbor an
important number of MSCRAMM genes, including the four
gene clusters encoding predicted components of the E. faecium
pili (particularly the ebpEfm and the fms11-fms19-fms16 clus-
ters) (13, 31, 32), a finding that is consistent with the fact that
the presence of these genes appears to be more reliably asso-
ciated with members of the CC17 genetic lineage (11) than the
FIG. 3. Plasmids containing the fms20 gene or the fms21 gene (pilA), or both genes, in representative E. faecium isolates from the Andean
region of South America. (A) Genetic organization of fms20-fms21 (pilA) in E. faecium TX0016 (strain DO). This locus also contains a predicted
class C sortase-encoding gene (srtC4) and a class A sortase-encoding gene (srtA) (30). (B) S1 nuclease digestion of total DNA of E. faecium strains,
followed by PFGE (left panel) and hybridization with an fms20 probe (right panel). Lane 1, bacteriophage lambda ladder (molecular sizes [in
kilobases] are shown to the left); lanes 2 and 14, TX0016 (strain DO); lanes 3, ERV-99 (4); lanes 4, P1985 (Peru´); lanes 5, P1123 (Peru´); lanes
6, P2022 (Peru´); lanes 7, E417 strain (Ecuador); lanes 8, P1139 (Peru´); lanes 9, P575 (Peru´); lanes 10, P2074 (Peru´); lanes 11, E422 (Ecuador);
lanes 12, P1986 (Peru´); lanes 13, C1688 (Colombia); lanes 15, V2216 (Venezuela). Plasmid bands are shown as linearized fragments on the gel;
the white arrows indicate the plasmid bands hybridizing with the fms20 probe. (C) S1 nuclease digestion of total DNA of E. faecium strains,
followed by PFGE (left panel) and hybridization with an fms21 (pilA) probe (right panel). Lane 1, bacteriophage lambda ladder (molecular sizes
[in kilobases] are shown to the left); lanes 2 and 14, TX0016 (strain DO); lanes 3, ERV-99 (4); lanes 4, P1985 (Peru´); lanes 5, P1123 (Peru´); lanes
6, P2022 (Peru´); lanes 7, E417 (Ecuador); lanes 8, P1139 (Peru´); lanes 9, P575 (Peru´); lanes 10, P2074 (Peru´); lanes 11, E422 (Ecuador); lanes 12,
P1986 (Peru´); lanes 13, C1688 (Colombia); lanes 15, V2216 (Venezuela). The white arrows indicate the plasmid bands hybridizing with the fms21
(pilA) probe.
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presence of espEfm and hylEfm; and (iii) high-level of resistance
to ampicillin is commonly found in E. faecium isolates from the
region, with the majority of isolates exhibiting MICs of 64
g/ml.
Recently, a genotypic analysis of early clinical isolates of E.
faecium in the United States (11) showed that CC17 E. faecium
isolates have been circulating in the United States since at least
1982, and it was postulated that an ancestral genogroup of E.
faecium enriched with the fms genes was able to subsequently
acquire additional virulence and antibiotic resistance determi-
nants (such as espEfm, hylEfm, HLR to ampicillin, and the van
gene clusters) and establish itself as an epidemic hospital-
associated pathogen in the United States. Our results suggest
that the population genetics of VREfm in the northern region
of South America resembles that of isolates responsible for
early outbreaks in the United States (in about 1982) (11), and
it is tempting to speculate that an increase in the frequency of
E. faecium infections in South America may be expected in the
following decade as members of the hospital-associated lin-
eage disseminate and establish themselves as nosocomial
pathogens in the region. Nonetheless, it is important to point
out that the number of hospitals participating in this study
differed in each country; while 22 hospitals from six different
cities were represented in Colombia, a lower number of hos-
pitals in the other three countries participated in the study.
Thus, it is difficult to make countrywide generalizations of the
molecular epidemiology of enterococcal isolates in Peru´, Ven-
ezuela, and Ecuador. However, our data provide important
information on the type of organisms currently circulating in
the region.
An important goal of our study was to determine if South
American VREfm isolates also contain genes encoding puta-
tive pilus proteins that are present on plasmids coexisting with
hylEfm or vancomycin resistance gene clusters, as previously
shown for other strains (4, 17). Enterococcal pili are important
cell surface structures that have been implicated in the patho-
genesis of experimental endocarditis and urinary tract infec-
tions (24, 34). These trimeric units are composed of a major
backbone subunit and two minor subunits (36) with an N-
terminal signal sequence and a C-terminal cell wall-sorting
signal (30) encoded by different genes. Indeed, we found that
one of these clusters (fms20-fms21 [pilA]) is carried by large
plasmids in the majority of isolates studied. Moreover, in some
strains, the fms20-fms21 (pilA) cluster coexists on the same
plasmid with the hylEfm gene or with vanA, providing further
evidence that the plasmid dissemination of virulence, resis-
tance, and/or colonization determinants may be a strategy
adopted by hospital-associated lineages of E. faecium world-
wide. This finding also supports the hypothesis that the An-
dean region of South America may be in the early stages of an
E. faecium epidemic and that as the fms20-fms21/hylEfm-carry-
ing plasmids disseminate, the ability of the organisms to colo-
nize the gastrointestinal tract of patients and cause disease may
increase.
In summary, this is the first multicenter, multinational pro-
spective study of the molecular epidemiology of VR entero-
cocci in South America. Our results indicate that the preva-
lence of E. faecium is low among clinical isolates, but genotypic
analysis supports the fact that the population genetics of E.
faecium is similar to that seen in the United States more than
25 years ago, suggesting that the dissemination of these highly
adapted E. faecium organisms in the hospital environment may
occur in South America in the coming years through the clonal
expansion of hospital-adapted isolates and with the horizontal
transfer of virulence and colonization determinants.
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